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THE authors reported recently that endotoxaemia medi-
ated elevated levels oftumour necrosis factor (TNF-) and
interleukin-l (IL-I) were involved in the pathophysio-
logy of acute heat stroke patients. Pentoxifylline (PTX) is
known to modulate neutrophil functions. In the present
study the effects ofPTX on lipopolysaccharide (LPS) and
cytokine induced T-cell and macrophage (M) activation,
and on natural killer (NK) cell and lymphokine activated
killer (LAK) cell mediated cytotoxicity were examined.
Finally, the effect of PTX on the expression of adhesion
molecules (LFA-1, Mac-1 and ICAM-1), and cytokine
(IL-lff, IL-2, TNF-, IL-6 and IFN-y) production and their
surface receptor expression in response to LPS activation
was investigated. PTX free cultures served as a control.
Results revealed that PTX can down-regulate all the
above-mentioned immunological parameters in a dose-
dependent manner. These findings might have far
reaching clinical implications.
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Introduction
Cytokines and adhesion molecules play an
important role in normal immune regulation, 1’2
haematopoieses
3-5 and inflammatory responses.
6
Imbalances in the production of cytokines,
particularly those affecting inflammation response,
can have profound effects on immunoregulation
and may contribute to pathogenesis of numerous
diseases. 6’7 High physiological levels of cytokines
and enhanced expression and production of soluble
adhesion molecules have been implicated in a
number of clinical situations.
6 Recently, consider-
able interest has also been focused on the adhesion
molecules,s particularly for their role in pathogen-
esis during inflammatory processes. Cytokines are
known to activate4’9 a wide variety of killer lineage
cells, induce cytokine production and adhesion
molecules expression. PTX has been shown1’11 to
modulate neutrophil and monocyte functions. In
the present study, to understand the mechanism and
immuno-modulatory potential, the effects of PTX
on the activation of peripheral blood mononuclear
cells (PBMC), killer cells function, production of
cytokines, surface receptor expression of cytokines
and adhesion molecules was examined.
Materials and methods
Pentoxifylline" Lot 61H0058 was purchased from
Sigma (St Louis, MO, USA) and a stock solution
*A part of this work was presented at 8th International
Congress of Immunology Meeting, Budapest, Hungary, 23-28
August 1992.
of 1 mg/ml was prepared in sterile physiological
saline (Abbott Laboratories, IL, USA). Further
working dilutions were made in RPMI-1640 tissue
culture medium (Gibco, Grand Island, NY, USA).
Lipopo&saccharide: Serotype 026.86 was purchased
from Sigma, USA. Stock solution and working
dilutions were prepared in RPMI-1640 medium just
before use in various experiments.
Cytokines: Recombinant human IL-6 was purchased
from Genzyme Corp. (Boston, MA, USA),
recombinant human IL-2 (Batch No. C151597-02,
R0330) was kindly provided as a gift from
Hoffman-La Roche, Switzerland. All the cytokines
were reconstituted in RPMI-1640 and were diluted
further immediately before use.
4
Collection andpreparation ofperipheral blood mononuclear cells:
Samples (20-30 ml) of whole blood from healthy
individuals of either sex were collected into
heparinized tubes. PBMC were isolated by
Ficoll-Hypaque fractionation, cell count and
viability was carried out using the Trypan blue dye
(0.02%) exclusion method. PBMC were finally
suspended into RPMI-1640 medium supplemented
with 25 mM Hepes and glutamine, streptomycin
100/,g/ml, fungizone 25 #g/ml, penicillin 100 U/ml
and 10% AB human serum.
Activation of monocytes and PBMC: Monocytes were
isolated as described previously. 12’3 Six replicate
cultures of either bM (98% as judged by
non-specific esterases staining) or PBMC were set
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up for 72 h in complete RPMI-1640 medium at
37C, 5% CO2 as follows"
(a) PBMC (1 x 106/ml) q- IL-2 100 U or IL-6
100 U
(b) qM (1 x 106 ml) alone or + LPS 10/g/ml
(c) PBMC alone or + LPS 10 #g/ml
(d) PBMC+ LPS +PTX (0-250 ng/well/250 #1)
Effects of PTX on yIL-2, IL-6 and LPS induced
proliferation of PBMC was measured by [3H]TdR
uptake in culture (a) after 72h. Culture (b)
containing qM was used in antibody dependent
cytotoxicity (ADCC) type killer assays. Fresh
PBMC alone or after co-culturing with yIL-2
1000 U/1 x 106 PBMC/ml for 3 days were used as
effector cells for NK and LAK cell assays
respectively. PBMC from cultures (c and d) were
used to examine surface receptor expression for
various cytokines and adhesion molecules, whereas
supernatant from these cultures was used to
quantitate various cytokines. Unstimulated cultures
of PBMC and bM alone or with PTX were used
as a control.
dM, NK and LAK cell mediated killer cell assay: Using
K562 cells (erythroleukaemia cells, NK sensitive
target) or Daudi cells (Burkit lymphoma, NK
resistant target) as described previously
14-16 in a SlCr
release killer assay (qM 18 h assay using K562
target cells), or (NK and LAK cells in a 4 h assay),
specific cytotoxicity was measured at various
effector:target ratios (100:1, 50:1, 25:1, 12.5:1)
for M, NK or LAK cells. Spontaneous and
maximum SCr releases wert: also set up. Results
were computed as follows:
% specific cytotoxicity
SCr CPM exp SCr CPM spontaneous x 100
SlCr CPM max SlCr CPM spontaneous
Cytokine quantitation: Highly sensitive ELISA kits
from Endogen (Boston, MA, USA), Genzyme
Corp. and R & D System (USA) were used to
quantify IL-I, IL-2, TNF-, IL-6 and IFN-2 from
the supernatant collected from PBMC culture under
various conditions as described in the methodology.
Manufacturer’s guidelines were followed to meas-
ure these cytokines.4’7 Supernatant from PBMC
cultured without LPS and PTX were considered
negative controls, whereas supernatant from PBMC
plus LPS were considered positive controls.
Cytokine surface receptor assay: Using fluorokine kits
(British Biotechnology, R & D System, UK)
surface receptors for IL-I, IL-2 and TNF- were
measured on resting or activated (with LPS) PBMC
with or without co-culturing with PTX as
described earlier in the methodology. Manufac-
turer’s guidelines were followed to measure the
receptor of the cytokine using fluorescence
microscopy (Zeiss, Germany) or FACS (Flow
Cytometry). Results were expressed as a percentage
of positive cells compared with unactivated PBMC.
Expression of adhesions molecules LFA- 1, Mac- and
1CAM-l: Adhesion molecules (LFA-1, Mac-1 and
ICAM-1) on LPS activated PBMC (with or without
PTX) were measured by indirect labelling. PBMC
were first incubated with anti-LFA-1 (1:20 dilu-
tion), anti-Mac-1 (1:25 dilution) or anti-ICAM-1
(1:50 dilution, Bender & Co., Vienna, Austria)
monoclonal antibody for 1 h at room temperature.
After washing secondary labelling was carried out
using goat anti-mouse FITC antibody (1:25 dilu-
tion) for 45 min. Negative controls were set up by
excluding primary antibody. PBMC was analysed
with FACScan (Becton and Dickinson, USA) and
fluorescence microscopy (Zeiss, Germany). Results
were expressed as percentage of positive cells.
Statistical evaluation" The results were expressed as the
mean-t-the standard error (S.E.). The difference
between mean values was considered significant at
p _< 0.05. This was determined with Student’s t-test
when comparing two sets of means. A two-way
analysis of variance was employed for comparing
percentage of specific cytotoxicity under two differ-
ent conditions, inclusive of all effector" target ratios.
Results
Effects ofPTX on and cytokine induced activation ofPBMC:
PBMC activation either with LPS or cytokines, that
is IL-2 and IL-6, was down-regulated in a dose-
dependent manner when PTX was added to the
cultures at the initiation of the cultures (Fig. 1)
indicating suppressive effect on the pre-effector
level. Addition ofPTX to unstimulated PBMC had
no significant effect on [3H]TdR incorporation.
Once the PBMC had achieved their maximum
activations, additions of PTX was somewhat less
effective (results not shown). A maximum suppres-
sion was achieved at 250 ng/well/250/1 of PTX
concentration (p < 0.002 for IL-2; p < 0.023 for
IL-6 and p < 0.005 for LPS).
Effects of PTX on the dM mediated cytotoxicity: The
activated macrophages mediated cytotoxicity was
down-regulated in a dose-dependent manner
(Fig. 2) only when PTX was added to the cultures
at the initiation of cultures. Maximum suppression
in 4M cytotoxicity was only observed at 72 h,
results of 24 h and 48 h cytotoxicity assays in the
presence of PTX (data not shown) did not show
significant suppression. Addition of PTX (100 ng/
well/250#l) to similar cultures after 48h or
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FIG. 1. Effects of PTX (PTX-1 =50ng, PTX-2 100ng, PTX-3=
250 ng) on IL-2, IL-6 and LPS induced proliferation of PBMC. PTX
was introduced into the cultures at 0 h. Addition of PTX (250 ng) had no
significant effect on the [3H]TdR incorporation of unstimulated (control)
PBMC (data not shown). The results are mean Jr S.E. of three different
experiments.
72 h was less effective, whereas a minor (5-7%)
suppression was observed when PTX was added at
24 h to LPS stimulated cultures of 4M. A high
significant suppression (p < 0.005) at a 100"1
effector" target ratio was observed in the presence of
PTX _> 100ng/well when added at 0h to the
cultures.
Effects ofPTX on NK and LAK cell function: Addition
of PTX (10-250 ng/well/250/.tl) to both NK and
LAK cell assays at the initiation of cultures resulted
in a dose-dependent suppression (Fig. 3). A highly
significant suppression p < 0.001 was noted for
both NK and LAK cells at 250 ng PTX/well or
(1/g/ml) concentration. Addition of similar dose
of PTX during LAK cells assay, however, was not
effective (result not shown).
Effects of PTX on cytokine production and their receptor
expression: PBMC activated with LPS for 48 to 72 h
with or without PTX when analysed for the surface
receptor expression of IL-I, IL-2, TNF- and the
cytokine production of IL-1, IL-2, TNF-, IL-6
and IFN-2 in the supernatant of these cultures
indicated (Figs 4 and 5) a highly significant
(p < 0.001) suppression of cytokine production and
their surface receptor expression in the presence of
( < 0.05) PTX. Surface receptor expression and
production of IL-6 was only noticed at the higher
concentration of PTX (0.4 #g/ml).
Effects of PTX on adhesion molecule expression: Activated
PBMC when analysed for the expression of LFA-1,
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FIG. 2. Effects of various concentrations of PTX on )M mediated 18 h
cytotoxicity assay (measured against K562 target). Each point represents
the mean of triplicates with less than 5% variation. The results are
representative of one experiment from a total of three. Addition of PTX
to unstimulated )M had no significant effect (data not shown). O, LPS
activated M; O, +PTX 10 ng; A, +PTX 50 ng;/k, + PTX 100 ng;.,
unactivated (M.
MAC-l, ICAM-1 revealed a dose-dependent sup-
pression of LFA-1 and MAC-1 adhesion molecules
whereas ICAM-1 expression was modulated only
at higher concentrations of PTX (>_100ng/
10
6 PBMC/well) (Fig. 6).
Discussion
Polymorphonuclear neutrophils (PMN) partici-
pate significantly during certain pathological states
to induce a variety of cellular injuries.
18 Activation
ofPMN may lead to free oxygen radical production,
enhance cytotoxicity via proteolytic enzymes and
lead to increased adhesion to endothelial-cell
lining.
19-2 Several cytokines are known to activate
a wide variety of killer lineage cells, induce surface
receptor expression, induce the production of
adhesion molecules and lead to production of other
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FIG. . Modulation of N K and LAK cell function by various concentrations
of PTX. The results are the mean -i-S.E. of three different experiments.
cytokines. 4’s PTX mediated modulation of neutro-
phil functions has been reported in previous
studies. 11’22’23 The authors17 and others24’2s recently
showed that endotoxin induced cytokines i.e. IL-I
TNF- and IL-6 are implicated in the pathophysio-
logy of acute heat stroke patients. Imbalance in
cytokine or their soluble receptor production, killer
cell activation and adhesion molecule expression has
also been implicated in a number of diseases.26’27
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FIG. 4. Effects of PTX on in vitro cytokine production. The results are the
mean -t-S.E. of three different experiments, r-l, Control; I1, LPS; I, PTX
100 ng/ml.
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FIG. 5. Effects of PTX on the surface receptor expression on various
cytokines. The results are the mean +_ S.E. of three different experiments.
The aim of the present study was to analyse to what
degree PTX interferes with various immune cell
functions that are thought to play roles in a variety
of normal and abnormal inflammatory states.
The results of this study clearly demonstrate that
PTX can block activation and subsequent gen-
eration of killer lineage cells in a dose-dependent
manner. LPS induced nonspecific activation of
PBMC or cytokine mediated cytotoxicity, as
measured either by using [3H]TdR uptake or
cytotoxicity assay, was significantly suppressed,
when PTX was added at the initiation of PBMC
100
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FIG. 6. Effects of PTX on the LPS induced surface adhesion molecules
expression on PBMC on day 3. The results are the mean -t-S.E. of three
different experiments. I-I, LFA-I’ i, Mac-l" I, ICAM1-1.
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proliferation or killer cell assay. The significant
suppression in mixed lymphocyte culture (MLR)
and subsequent generation of allo-specific cytotoxic
T-lymphocyte (CTL) killer cells (data not shown)
was only achieved at a high concentration of PTX
(_> 20 pg/ml), when PTX was introduced into the
culture at 0 h. Once the allo-specific CTL cytotoxic
killer cells were generated, addition of PTX even
at 10-20 pg/ml during the CTL assay was less
effective. An early report
28 on a phase I--II human
trial using PTX for the prevention of transplant
related toxicity following bone marrow transplant
(BMT), showed significant suppression in the level
of circulating TNF- and was associated with the
reduction in morbidity and mortality in patients
undergoing BMT. LPS induced cytokine (IL-1,
IL-2, IL-6, TNF-0 and IFN-y) and surface receptor
expression of IL-, IL-2 and TNF- were
significantly affected only when PTX was added at
the beginning of the culture, indicating that once
the maximum activation of PBMC had been
achieved, PTX was no longer able to suppress the
production of these cytokines. However, a recent
:tudy
29 showing a differential effect of PTX on
TNF- and IL-6 production in vivo in response to
OKT3 monoclonal antibody in transplant patients
clearly demonstrated a different mechanism ofPTX
action, depending on the cellular origin of these
cytokines and the availability of accessory cells
which can modulate the antigen presentation during
induction of cytokine production. In the present
study the effect of PTX on LPS stimulated PBMC,
not on the pure macrophages population was
measured. The amount of cytokines produced is the
total amount secreted by T-lymphocytes and
macrophages together, so a selective effect of PTX
on either population of cells producing cytokines
cannot be differentiated.
The expression of adhesion molecules, LFA-1,
Mac-1 and ICAM-1, on PBMC was significantly
affected by PTX at higher concentrations only.
Modulation of various adhesion molecules on
human endothelial cells activated with various
cytokines was less affected using similar concen-
trations of PTX (R. S. Parhar and S. Al-Sedairy,
manuscript in preparation) indicating that regula-
tion of endothelial cell surface adhesion molecule
expression could be different to that of PBMC.
IL-1, IL-2, TNF-, IL-6 and IFN-2 are implicated
in the pathogenesis of several clinical settings
including arthritis, septic shock, hyperthermia and
organ transplantation. A high level of soluble
ICAM-1 adhesion receptor has been reported in
malignant melanoma patients.
3 The ability ofPTX
to suppress surface receptor expression of adhesion
molecules merits further study to evaluate its role
in malignant diseases. PTX has recently been shown
to inhibit mRNA expression of TNF-29 in PBMC
and TNF- and IL-1/ in HL-60 leukaemia cells.
31
Though the precise inhibitory mechanism of PTX
at the molecular level is still elusive, its ability to
down-regulate the cytokine surface receptor expres-
sion and cytokine production appears to be
the key mechanism in down-regulating the
activation of leukocytes macrophages, NK and
LAK cell mediated cytotoxicity. Since the surface
receptor expression of IL-I, IL-2, TNF-, IFN-
and adhesion molecules on killer lineage cells is
related to cell activation and cytotoxic state, it is
speculated that the mechanism of the PTX effect
may be explained by its ability to down-regulate and
suppress the mRNA of inflammatory cytokines
which subsequently induce adhesion molecule
expression and their production. The ability of
PTX to down-regulate, modulate and suppress
killer lineage cell function, cytokine and adhesion
molecule expression and production, respectively,
warrant studies in various clinical settings to
evaluate its therapeutic benefits.
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